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1 A survey of non-depolarising muscle relaxants used in cardiac anaesthesia and surgery
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Introduction: Residual neuromuscular blockade contributes to
postoperative morbidity and mortality, and is more common with
long-acting non-depolarising muscle relaxants (NDMRs) such as
pancuronium [1]. This phenomenon may be a common occurrence
in ‘fast-track’ managed cardiac patients administered long-acting
NDMRs. We examine the usage of NDMRs in cardiac anaesthesia
in the United Kingdom.
Methods: A postal questionnaire was sent to 310 consultant
cardiac anaesthetists in the United Kingdom. We asked which
NDMRs are preferred (differentiating between ‘fast-track’ [FT] and
‘non-fast-track’ [NFT] management of patients), and what methods
are used to assess neuromuscular function prior to extubation.
Results: There was a 72.6% (225/310) response rate, of which
217 responses were valid. A single-agent NDMR technique is
most prevalent for both NFT (92.2%) and FT patients (88.5%).
Pancuronium (either as sole agent or in combination with another
NDMR) was the first choice for NFT and FT patients, 73.7% and
52.1% respectively. For both management strategies, rocuronium
is the next most popular agent. Benzylisoquinolinium derivatives are
not in common usage. Forty-nine out of 211 anaesthetists (where a
comparison could be made) changed their choice of NDMR
between NFT and FT patients. The majority of these anaesthetists
(85.7%) remove pancuronium from their practice for FT patients.
Of respondents, 20.7% (45/217) indicated that an assessment of
neuromuscular function was part of an extubation protocol; 75.6%
(34/45) of these respondents detailed only clinical methods, whilst
6.7% (3/45) indicated use of a ‘neuromuscular function monitor’
alone, with 15.6% (7/45) indicating use of both methods. Amongst
the responses indicating ‘neuromuscular function monitor’ methods,
an assessment of the ‘train-of-four’ was the commonest response.
Less than 10% monitor the neuromuscular junction during surgery.
Conclusions: Pancuronium remains the most popular NDMR for
all types of cardiac anaesthesia. Some anaesthetists modify their
choice of NDMR for FT management, changing from pancuronium
to a shorter acting NDMR as the commonest adaptation. A minority
of respondents indicated that a protocol exists to routinely assess
the neuromuscular function prior to extubation.
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Introduction: Many patients develop, to a varying extent, a meta-
bolic acidosis during cardiopulmonary bypass (CPB). Often this
acidosis is assumed to be the result of tissue hypoperfusion.
However, fluids administered to patients before and during CPB,
through their effects upon the strong ion difference (SID), may
cause metabolic acidosis [1,2]. These fluids may also produce
acidosis by haemodilution because of the decrease in plasma
protein concentration [2]. The aim of this study was to determine
whether metabolic acidosis occurring during CPB is the result of
hypoperfusion or is iatrogenic.S2
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Methods: Forty-nine adult patients undergoing cardiac surgery
with CPB were studied. Arterial blood was sampled before the
induction of anaesthesia during the re-warming phase of CPB
(35°C). Blood gas analysis and concentrations of electrolytes,
plasma proteins and lactate were measured. The volumes and
compositions of fluids administered were recorded.
Results: Factors that were found to correlate significantly (P < 0.05)
with the change in hydrogen ion concentration between the two time
points were identified. Change in arterial carbon dioxide concentra-
tion was used to remove the respiratory component of acidosis.
These predictor factors were then entered after change in arterial
carbon dioxide tension, to first remove the respiratory component of
acidosis, into a multivariate linear regression model (P < 0.001,
r2 = 0.65) so as to examine their influence on the change variance in
hydrogen ion concentration. Only the amount of sodium bicarbonate
administered (β = –0.404, P < 0.001) and the change in SID (β
= –0.339, P = 0.004) were found to predict the change in hydrogen
ion concentration. Change in lactate concentration (P = 0.072) and
the total volume of fluid administered moderated by body surface
area (P = 0.523) were excluded from the model.
Discussion: Our sample size is underpowered to detect factors
that might have a small effect size. Also, the regression model only
explained 65% of the variance so factors other than those that we
have identified influence the change in hydrogen ion concentration.
However, our findings suggest that metabolic acidosis arising
during CPB is largely induced by change in the SID and the type of
fluids administered, whilst haemodilution and hypoperfusion do not
appear to have important roles in its genesis. Whether this meta-
bolic acidosis or its correction has any influence on outcome from
cardiac surgery merits further research.
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Objective: To audit the outcome of patients admitted to a general
intensive care unit (ICU) from a thoracic high dependency unit
(HDU) after pulmonary resection.
Methods: A retrospective case note review of 28 consecutive
patients (22 male, six female; median age, 66 years [range,
48–80 years]) admitted to the ICU following initial recovery on an
HDU after pulmonary resection, in a 3-year period, in a single
surgeon thoracic surgical practice.
Results: ICU and 6-month mortalities were 47% (13 patients) and
64% (18 patients), respectively. Need for mechanical ventilation
(P = 0.006) and subsequent renal support (P = 0.05) were predic-
tors of hospital mortality on multivariate analysis. All four patients
who required both ventilation and renal support died. Only two of
17 patients (12%) who required mechanical ventilation were alive
at 6 months (P = 0.002). Age, sex, preoperative pulmonary func-
tion, extent of resection, diagnosis, need for reoperation and
inotropic requirements were not predictors of poor outcome.
Patients who died in the ICU (n = 13) stayed for longer (mean,
17.6 days versus 5.3 days; P = 0.04) and at a higher average cost
per patient (£21,992 versus £5300; P = 0.04) than those who
survived (n = 15).
Conclusions: Mechanical ventilation for subsequent respiratory
complications after initial recovery from lung resection is generally
not worthwhile.
Hospital mortality  6-month mortality
Age
< 70 years 47% (9 of 19) 63% (12 of 19)
> 70 years 44% (4 of 9) 67% (6 of 9)
FEV1%
< 70% predicted 27% (3 of 11) 64% (7 of 11)
> 70% predicted 59% (10 of 17) 65% (11 of 17)
Histology
Malignant 43% (10 of 23) 65% (15 of 23)
Benign 60% (3 of 5) 60% (3 of 5)
Mechanical ventilation
Yes 76% (13 of 17) 88% (15 of 17)
No 0% (0 of 11) 27% (3 of 11)
Renal support required
Yes 73% (11 of 15) 87% (13 of 15)
No 15 % (2 of 13) 38% (5 of 13)
FEV1%, forced expiratory volume in 1 s as a percentage of forced vital
capacity.S3
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4 Significance of apoptosis in ischaemia and reoxygenation of the human myocardium
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Background: Apoptosis is triggered by a number of intrinsic and
extrinsic factors but its importance in ischaemia–reoxygenation in the
human heart is unclear. We quantified apoptosis and necrosis in an
in vitro model of human atrial myocardium following various periods
of simulated ischaemia (SI) and reoxygenation (R).
Methods: Experiments (n = 8 per group) were performed on sec-
tions of right atrium subjected to periods of SI (0, 30, 90 and
180 min) followed by R (2, 8 and 24 hours). Cell damage was
measured following release of myocyte-specific creatine kinase
(CK-MB) and cell viability measured using the vital stain MTT. Cell
apoptosis and necrosis were visualised in tissue sections with
FITC (TUNEL) and propidium iodide, respectively. Quantification
was by confocal microscopy and NIH-image software. Caspase-3-
like activity was quantified by fluorometric assay.
Results: CK-MB release and necrosis increased whereas MTT
values decreased over the period of SI in a dose-dependent
manner. Apoptosis increased (32%) after 90 min SI with 2 hours R
and peaked (56%) after 90 min SI with 8 hours R. Apoptosis
declined following 180 min R. The smallest induction of apoptosis
occurred after 24 hours R. With increasing SI in the 2 hour proto-
col, there was a progressive rise in the ratio of caspase-3 to total
caspase activity, which increased to a maximum of fourfold after
180 min SI and 2 hours R. Caspase-3 levels were similar to fresh
tissue after 24 hours.
Conclusions: In this model of SI/R injury of human myocardium, the
degree of apoptosis and necrosis varies with the duration of
ischaemic insult and the reoxygenation time. After certain periods of
ischaemia, apoptosis may be the predominant pathway to cell death.
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Background: Patients with diabetes mellitus have a worse hospital
and long-term outcome after coronary artery bypass grafting
(CABG) [1]. It has been shown that the non-insulin diabetes melli-
tus (NIDDM) group of patients on oral sulphonylureas have a higher
mortality than those treated with insulin (IDDM) following myocardial
infarction [2]. Oral sulphonylureas abolish ischaemic precondition-
ing, which is an important cardiac protective mechanism during the
perioperative period of CABG [2]. Insulin resistance and hyper-
glycaemia decrease arterial compliance, promote plaque growth
and cause contractile dysfunction of the myocytes [3].
Objective: To analyse retrospectively outcome data in patients
with NIDDM on oral sulphonylureas who underwent CABG.
Methods: From a total of 2537 patients who had CABG, outcome
data was identified in 236 patients with NIDDM and in 130
patients with IDDM over a 2-year period (April 1999–March 2001).
We compared the mortality, length of hospital stay, length of stay
in the intensive care unit (ICU), reoperation rate, ICU re-admission
rate and duration of operation with control patients, matched with
respect to surgeon and risk score (EuroSCORE). We also com-
pared the incidence of diabetes in Europe and North America with
Papworth.
Results: There was no difference in length of hospital stay, length
of ICU stay, reoperation rate, ICU re-admission rate and the dura-
tion of operation.
Conclusions: There is a higher mortality in the NIDDM group of
patients compared with the IDDM and the non-diabetic group after
CABG. Intensive insulin therapy in critically ill postoperative
patients showed a reduction in hospital mortality and morbidity
from renal failure, blood stream infections and polyneuropathy, and
reduced red cell transfusion requirement [4]. Assessment of
diabetic patients in the pre-assessment clinics, stopping sulphonyl-
ureas and converting to insulin preoperatively and to tight blood
glucose control perioperatively, may help improve outcome in this
group of patients.
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Introduction: Severe perioperative bleeding in cardiac surgery is
multifactorial in origin. Recombinant factor VIIa (rFVIIa; Novo
Nordisk, Denmark) has been used perioperatively since 1988 [1]. It
promotes formation of blood clots by a range of actions. We have
recently introduced it into our cardiac surgical programme for
severe intractable coagulopathic bleeding.
Purpose of study: To assess efficacy and safety of rFVIIa in
cardiac surgery by chart review.
Methods: Charts for the seven patients who received rFVIIa were
reviewed for effects on clinical status, blood loss and transfusion need.
Results: Seven adult patients had received rFVIIa for severe
cardiac surgical bleeding by February 2002. Five of these survived
to hospital discharge. Of the two deaths, one patient died of con-
tinued haemorrhage on the operating table, and the other died at
5 days postoperation from multiple organ failure. The median total
dose of rFVIIa administered was 22 µg/kg (range, 13–75 µg/kg).
There were marked reductions in estimated hourly blood loss from
a median 952 ml/hour (range, 182–1500 ml/hour) to a median
19 ml/hour (range, 7–41 ml/hour) after rFVIIa in the survivors.
Reductions in blood product use were also noted (Table 1).
Conclusions: There have been two published reports on the use
of rFVIIa in cardiac surgery involving one and five patients, respec-
tively [2,3]. In this review, we have found that five out of seven
patients all with severe perioperative bleeding appeared to benefit
from the administration of rFVIIa. There were no thrombotic compli-
cations noted. Further research into the optimal role for rFVIIa in
cardiac surgery is justified.
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Table 1
Median units of blood product used for the five surviving
patients (range)
Product Before Novo7 After Novo7
Fresh frozen plasma 2 (0–12) 0
Platelets 2 (2–4) 0 (0–3)
Cryoprecipitate 10 (0–10) 0
Beriplex 1000 (0–1000) 0
7 A comparison of rocuronium and pancuronium in adult patients scheduled for ‘fast-track’ elective
open heart surgery involving hypothermic cardiopulmonary bypass
R Thomas, D Smith, P Strike
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Introduction: The non-depolarising muscle relaxant (NDMR) pancuro-
nium continues to be used for fast-track cardiac anaesthesia despite
its declining popularity elsewhere. Its duration of action can be unpre-
dictable and prolonged, leading to an increased incidence of residual
neuromuscular block [1]. We examined whether pancuronium remains
an appropriate NDMR for ‘fast-track’ patients and include comparison
with rocuronium, which has been suggested as an alternative agent.
Methods: Twenty patients eligible for ‘fast-track’ cardiac surgery
were prospectively randomised to receive either pancuronium
0.1 mg/kg or rocuronium 1 mg/kg in a double-blind study design.
Neuro-muscular function was assessed by acceleromyography and
the time to recovery of train-of-four (TOF) ratio of 0.9 was mea-
sured. A standardised anaesthetic technique was employed which
avoided the use of volatile anaesthetic gases and vapours.S5
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Results: Both groups had similar demographic makeup and were
well matched for confounding variables. No patient required sup-
plementary doses of NDMR.
The median times (in minutes) for pancuronium and rocuronium,
respectively, to recovery of TOF 0.9 were 472.5 (SD, 103.7) and
217.5 (SD, 56.6). The observed difference in TOF 0.9 medians
was 255 (95% CI, 150–320). The Mann–Whitney test was highly
significant at P = 0.0003.
No patient in the rocuronium group and 7/10 patients in the pan-
curonium group had their extubations delayed as a consequence
of residual paralysis.
Conclusions: We have demonstrated that pancuronium lasts
approximately twice as long and has approximately double the inter-
individual variation compared with rocuronium. We recommend that
pancuronium is no longer an acceptable NDMR in such patients.
Although rocuronium has potential as an alternative agent, we
recommend that due to variation in its duration of action post-
hypothermic cardiopulmonary bypass, patients should routinely
have their neuro-muscular function monitored prior to extubation.
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A 59-year-old patient undergoing placement of a left ventricular
assist device had a substernal epicardial echocardiography
imaging technology device inserted intraoperatively. This was used
postoperatively in the intensive care unit to optimise the patient’s
haemodynamic status and facilitate weaning from an intra-aortic
balloon pump and inotropic support.
Substernal epicardial echocardiography (SEE) is a new echocardio-
graphy technique [1]. This is a modified chest drainage tube with a
dual lumen creating an insertion pathway accommodating a trans-
oesophageal echo (TOE) probe, while also acting as a mediastinal
chest drain tube. The TOE probe lies within a blind-ended ‘sock’
along the underside of the chest drain. The device is placed in an
anterior epicardial position prior to closure of the sternum, and allows
the subsequent insertion of a standard TOE probe, allowing post-
operative echocardiographic imaging of the heart. The chest tube
sock permits rotational and vertical manipulation of the TOE probe.
We present the images obtained with the SEE and concur with a
previous study that the quality of the images shown is excellent [2].
We conclude that this novel echo mode can be used serially in the
intensive care unit to accurately assist in the assessment of ventric-
ular function and filling during weaning of an intra-aortic balloon
pump and inotropic drugs.
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